Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreementThe overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 – Genmab A/S (NASDAQ:GMAB) announced today that it will assume sole responsibility for the continued development and potential c ...